Has Welcure Drugs declared dividend?

No Dividend History Available

Who are the peers of the Welcure Drugs?

Welcure Drugs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Welcure Drugs has below-average management and capital structure risks, with average growth, but boasts the highest 1-year return of 146.68% among its peers.

Peers: The peers of Welcure Drugs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Parnax Lab, Mangalam Drugs, Source Natural, Bharat Immunolog, and Samrat Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Source Natural, while Good management risk is found at Divi's Lab., Torrent Pharma, and Samrat Pharma. Below Average management risk is seen at Parnax Lab, Welcure Drugs, and Bharat Immunolog, while Average management risk is noted at Mangalam Drugs. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, and Mangalam Drugs. Average growth is observed at Welcure Drugs, and the rest show Good growth. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, and Parnax Lab, while Good capital structure is found at Torrent Pharma and Source Natural. Below Average capital structure is noted at Welcure Drugs, Mangalam Drugs, and Bharat Immunolog.<BR><BR>Return Snapshot: Welcure Drugs has a 1-year return of 146.68%, which is the highest among its peers, while Bharat Immunolog has the lowest at -8.98%. The six-month returns for Mangalam Drugs, Parnax Lab, and Bharat Immunolog are negative.

What is the technical trend for Welcure Drugs?

As of May 8, 2025, Welcure Drugs shows a bullish technical trend supported by strong MACD, Bollinger Bands, and moving averages, though caution is advised due to a mildly bullish weekly Dow Theory trend.

As of 8 May 2025, the technical trend for Welcure Drugs has changed from mildly bullish to bullish. The weekly and monthly MACD are both bullish, indicating strong momentum. Bollinger Bands also reflect a bullish stance on both time frames. Daily moving averages are bullish, supporting the upward trend. The KST is bullish on both weekly and monthly charts, further confirming the positive outlook. However, the Dow Theory shows a mildly bullish trend on the weekly but no trend on the monthly, suggesting some caution. Overall, the current technical stance is bullish with strong indicators supporting this view.

Who are in the management team of Welcure Drugs?

As of March 2022, the management team of Welcure Drugs includes Sudhir Chandra (Managing Director), D C Jain, Gagan Juneja, and Mohd. Shahbaz Alam (Non-Executive & Independent Directors), along with Mitashi Bisaria (Director & Company Secretary), Sitaben S Patel, and Rajeev Mehra (Additional Directors). Each member plays a key role in the company's governance and management.

As of March 2022, the management team of Welcure Drugs consists of the following individuals:<BR><BR>1. D C Jain - Non-Executive & Non-Independent Director<BR>2. Sudhir Chandra - Managing Director<BR>3. Mitashi Bisaria - Director & Company Secretary<BR>4. Gagan Juneja - Non-Executive & Independent Director<BR>5. Mohd. Shahbaz Alam - Independent Director<BR>6. Sitaben S Patel - Additional Director<BR>7. Rajeev Mehra - Additional Director<BR><BR>Each member has distinct roles contributing to the governance and management of the company.

What does Welcure Drugs do?

Welcure Drugs & Pharmaceuticals Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 1992, with recent quarterly net sales of ₹212 Cr and a net profit of ₹25 Cr as of March 2025. The company focuses on manufacturing bulk drugs and has a market cap of ₹138 Cr.

Overview:<BR>Welcure Drugs & Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History:<BR>Incorporated on June 4, 1992, Welcure Drugs And Pharmaceuticals (WDPL) has undergone various developments, including a public issue in August 1994 to finance a project for manufacturing bulk drugs in Rajasthan. The latest reported quarterly results indicate net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 212 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 25 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 138 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 31.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.01 <BR>Return on Equity: 328.36% <BR>Price to Book: 97.99 <BR><BR>Contact Details:<BR>Address: B-9 & 10 Laxmi Towers, L S C Block-C Saraswati Vihar Delhi New Delhi : 110034 <BR>Tel: 91-011-2701 1428 <BR>Email: investor.welcure@gmail.com <BR>Website: https://welcuredrugs.com

Who are the top shareholders of the Welcure Drugs?

The top shareholders of Welcure Drugs are primarily individual investors, holding 98.99% of the shares, with Rahul Ratansingh Sikarwar being the largest individual shareholder at 9.78%. There are no institutional investors or pledged promoter holdings.

The top shareholders of Welcure Drugs primarily consist of individual investors, who hold a significant 98.99% of the company's shares. Among public shareholders, the highest individual shareholder is Rahul Ratansingh Sikarwar, with a holding of 9.78%. There are no institutional investors or mutual funds currently holding shares in the company, and there are no pledged promoter holdings.

How big is Welcure Drugs?

As of 24th July, Welcure Drugs & Pharmaceuticals Ltd has a market capitalization of 114.00 Cr, classifying it as a Micro Cap, with recent net sales of 46.64 Cr and net profit of 4.40 Cr over the latest four quarters. Data for shareholder's funds and total assets is unavailable.

As of 24th July, <BR><BR>Market Cap: Welcure Drugs & Pharmaceuticals Ltd has a market capitalization of 114.00 Cr, categorizing it as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 46.64 Cr, while the sum of Net Profit for the same period is 4.40 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is the latest annual period. However, data for Shareholder's Funds and Total Assets is unavailable.

When is the next results date for Welcure Drugs?

Welcure Drugs will announce its results on 05 August 2025.

Welcure Drugs will declare its results on 05 August 2025.

Are Welcure Drugs latest results good or bad?

Welcure Drugs reported exceptionally strong financial results for the quarter ending June 2025, with net sales of Rs 321.12 crore and a profit after tax of Rs 23.30 crore, reflecting significant year-on-year growth. Overall, the results are very good, indicating strong growth and profitability despite a slight decrease in growth rates compared to the previous quarter.

Welcure Drugs has reported exceptionally strong financial results for the quarter ending June 2025. The company achieved net sales of Rs 321.12 crore, which represents an extraordinary year-on-year growth of over 32,111,999,900%. This is a significant increase from Rs 25.43 crore in the previous year.<BR><BR>In terms of profitability, the profit before tax (PBT) reached Rs 31.14 crore, reflecting a remarkable growth of 5510.8% compared to the average PBT of Rs 0.56 crore from the previous four quarters. The profit after tax (PAT) was reported at Rs 23.30 crore, which is a substantial increase of 2184.3% over the average PAT of Rs 1.02 crore in prior quarters.<BR><BR>Additionally, the operating profit (PBDIT) also hit its highest level in the last five quarters at Rs 31.13 crore, and the earnings per share (EPS) rose to Rs 2.07, indicating improved profitability for shareholders.<BR><BR>While there has been a decrease in the growth rates compared to the previous quarter, the overall financial performance indicates a strong trajectory for Welcure Drugs. Therefore, the latest results can be considered very good, showcasing significant growth and profitability.

Is Welcure Drugs overvalued or undervalued?

As of September 15, 2025, Welcure Drugs is considered an attractive investment due to its low PE ratio of 3.41 and significant undervaluation compared to peers like Sun Pharma and Divi's Lab, despite a year-to-date return of -28.11%.

As of 15 September 2025, the valuation grade for Welcure Drugs has moved from very attractive to attractive. The company is currently considered undervalued, given its low PE ratio of 3.41, a price-to-book value of 0.92, and an EV to EBITDA of 6.45. These ratios indicate that the stock is trading at a significant discount compared to its earnings and book value.<BR><BR>In comparison to its peers, Welcure Drugs stands out with a much lower PE ratio than Sun Pharma (33.52) and Divi's Lab (69.55), both of which are classified as expensive. Additionally, its PEG ratio of 0.01 further emphasizes its undervaluation relative to the industry. Despite recent stock performance trailing the Sensex, particularly with a year-to-date return of -28.11% compared to the Sensex's 4.67%, the fundamental metrics suggest that Welcure Drugs presents a compelling investment opportunity at its current price.

What is the bonus history of Welcure Drugs?

Welcure Drugs has announced a 1:10 bonus issue, with an ex-date and record date set for October 16, 2025. Shareholders will receive 1 additional share for every 10 shares held.

Welcure Drugs has a recent bonus issue history where they announced a 1:10 bonus issue. The ex-date for this bonus is set for October 16, 2025. This means that for every 10 shares held, shareholders will receive 1 additional share as a bonus. The record date for this bonus is also October 16, 2025. If you have any more questions about Welcure Drugs or need further details, feel free to ask!

How has been the historical performance of Welcure Drugs?

Welcure Drugs experienced a significant turnaround in the fiscal year ending March 2025, reporting net sales of 24.55 crore and a profit after tax of 2.17 crore, compared to losses in the previous year. This marked its first year of substantial revenue generation and profitability, with improved operating and profit margins.

Answer:<BR>The historical performance of Welcure Drugs shows significant changes, particularly in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Welcure Drugs reported net sales of 24.55 crore, a notable increase from previous years where sales were non-existent. The total operating income also rose to 24.55 crore, reflecting the same trend. The company's total expenditure, excluding depreciation, was recorded at 23.67 crore, which is a substantial increase from 0.23 crore in March 2024. Operating profit (PBDIT) for March 2025 was 2.79 crore, a recovery from a loss of 0.14 crore in the previous year. Profit before tax reached 2.78 crore, compared to a loss of 0.17 crore in March 2024, leading to a profit after tax of 2.17 crore, up from a loss of 0.17 crore. The earnings per share (EPS) improved to 0.02 from a negative 0.13 in the prior year, indicating a positive shift in profitability. The operating profit margin for March 2025 was 3.58%, and the profit after tax margin stood at 8.84%, both reflecting a strong performance compared to the previous years where these metrics were at zero. Overall, the financial results for March 2025 demonstrate a significant turnaround for Welcure Drugs, marking its first year of substantial revenue generation and profitability.

Should I buy, sell or hold Welcure Drugs?

Which are the latest news on Welcure Drugs?

Why is Welcure Drugs falling/rising?

As of 04-Dec, Welcure Drugs & Pharmaceuticals Ltd's stock price is at 0.53, down 3.64%, and has underperformed its sector. The stock has declined 49.54% year-to-date, despite a recent monthly increase, indicating a persistent bearish trend.

As of 04-Dec, Welcure Drugs & Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 0.53, which reflects a change of -0.02 or -3.64%. The stock has underperformed its sector by -3.93% today and has been on a consecutive downward trend, losing -7.02% over the last two days. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>In the broader context, the stock has seen a significant year-to-date decline of -49.54%, contrasting sharply with the Sensex, which has gained 9.12% during the same period. Although there was a positive performance in the last month with a rise of +3.92%, this has not been sufficient to offset the overall negative trajectory observed in the longer term.<BR><BR>Despite a recent increase in investor participation, with a delivery volume rise of 50.89% against the 5-day average, the overall sentiment remains negative, contributing to the stock's current decline.